LucentAD
At Lucent Diagnostics, we are proud to unveil our breakthrough product, LucentAD. Designed to transform the landscape of Alzheimer’s disease diagnostic testing, LucentAD uses cutting-edge technology to provide accurate and actionable results from a blood sample and empower healthcare professionals while improving patient outcomes.
With LucentAD, Lucent Diagnostics aims to address the critical need for advanced diagnostic tools that can measure biomarkers associated with neurodegenerative diseases, such as phosphorylated Tau (p-Tau). Our innovative solution provides clinicians with the information they need in conjunction with other diagnostic tools, to make informed decisions and optimize patient care.
Alzheimer’s Pathology Detection Made Simple
The recent emergence of promising new Alzheimer’s therapies has brought to light an urgent need for improved tools to help diagnose the disease in its early stages when therapeutic intervention is most likely to deliver clinical benefit.
Key Features of the LucentAD Assay
- Unrivaled Sensitivity: LucentAD’s technology enables the detection and quantification of biomarkers at ultra-low levels, offering sensitivity and precision.
- Less Invasive Sampling: By measuring levels of p-Tau in blood, such as p-Tau181 which is a key biomarker associated with Alzheimer’s pathology, LucentAD helps enable more timely decision making and an improved experience for the patient.
- Streamlined Workflow: Our user-friendly interface and intuitive design streamline the diagnostic process, ensuring efficiency and minimizing the time required for test completion.
- Research and Development: Lucent Diagnostics remains committed to ongoing research and development, continuously striving to optimize the use of LucentAD as well as to explore new biomarkers to expand our diagnostic test offerings in the future.
Comprehensive and Personalized Approach
At Lucent Diagnostics, we are dedicated to revolutionizing healthcare through innovative diagnostic solutions. LucentAD is poised to transform the way neurodegenerative diseases are diagnosed, monitored, and treated.
Test Specifications
View details on our CLIA-validated laboratory-developed test, LucentAD, for the quantitative determination of p-Tau 181 in EDTA plasma.
Join Us Today
Join us on this transformative journey. Discover how LucentAD, powered by Quanterix, can empower you with the knowledge and confidence to navigate the complexities of Alzheimer’s disease. Take control of your health and unlock a brighter future today.